Harbin Gloria Pharmaceuticals Co., Ltd

002437

CNE100000QG8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
2.14 ^CNY	+2.39%		+7.54%	-14.74%

Apr. 26	HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 12	HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	CI

HARBIN GLORIA PHARMACEUTICALS Co., LTD(XSEC:002437) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Harbin Gloria Pharmaceuticals Co., Ltd

HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD completed the acquisition of additional 10% stake in Harbin Dandelion Pharmaceuticals Co., Ltd. from Harbin Hanjun Investment Co., Ltd.	23-10-27	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD agreed to acquire additional 10% stake in Harbin Dandelion Pharmaceuticals Co., Ltd. from Harbin Hanjun Investment Co., Ltd. for CNY 35 million.	23-10-16	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD(XSEC:002437) added to S&P Global BMI Index	23-09-18	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2023	23-07-28	CI
Harbin Gloria Pharma Offloads Entire 42% Stake in Biotech Unit for 240 Million Yuan	23-06-29	MT
Harbin Gloria Pharma Offloads Entire 42% Stake in Biotech Unit for 240 Million Yuan	23-06-29	MT
Qingdao Pusheng Puli Enterprise Management Center (Limited Partnership) agreed to acquire 42.1204% stake in Guangzhou Gloria Biosciences Co., Ltd. from HARBIN GLORIA PHARMACEUTICALS Co., LTD for CNY240 million.	23-06-28	CI
HARBIN GLORIA PHARMACEUTICALS Co., LTD announced that it expects to receive CNY 300 million in funding	23-05-14	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-23	CI
Consortium of buyers completed the acquisition of a 32.13% stake in Harbin Gloria Pharmaceuticals Co., Ltd from Harbin Gloria Group Co., Ltd.	23-04-06	CI
Harbin Gloria Pharma Swings to Loss in 2022 on Asset Impairment	23-01-11	MT
Harbin Gloria Pharmaceuticals Co., Ltd Announces Executive Appointments	22-12-21	CI
Harbin Gloria Pharmaceuticals Co., Ltd Approves Executive Appointments	22-11-14	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-28	CI
Guangzhou Gloria Biosciences Co., Ltd. announced that it expects to receive CNY 200 million in funding from Harbin Gloria Pharmaceuticals Co., Ltd	22-05-12	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-25	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-25	CI
Harbin Gloria Pharmaceuticals Co., Ltd(XSEC:002437) dropped from S&P Global BMI Index	21-12-20	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-28	CI
Harbin Gloria Pharmaceuticals Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
Harbin Gloria Pharmaceuticals Co., Ltd Announces Earnings Results for the First Quarter Ended March 31, 2021	21-04-28	CI

Chart Harbin Gloria Pharmaceuticals Co., Ltd

Duration

Period

Chart Harbin Gloria Pharmaceuticals Co., Ltd

More charts

HARBIN GLORIA PHARMACEUTICALS Co., LTD is a China-based company, principally engaged in the manufacture and distribution of pharmaceuticals. The Company's products include cardiovascular and cerebrovascular drugs, orthopedic drugs, nutritional drugs, anti-infective drugs, immune-enhancing drugs, diabetes drugs, antineoplastic drugs and electrolytes drugs. The Company is also engaged in the agency, research and development of pharmaceuticals, the provision of clinical services and financial investment business. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-05-10 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
HARBIN GLORIA PHARMACEUTICALS CO., LTD	-14.74%	655M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.81%	43.34B
OTSUKA HOLDINGS CO., LTD.	+20.44%	21.96B
SANDOZ GROUP AG	+13.30%	14.09B
CIPLA LIMITED	+12.97%	13.64B
ZYDUS LIFESCIENCES LIMITED	+39.74%	11.43B
ONO PHARMACEUTICAL CO., LTD.	-8.59%	6.86B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+9.64%	5.22B